Other languages Sutro Biopharma, Inc.

Equities

STRO

US8693671021

Real-time Estimate Cboe BZX Other stock markets 11:44:54 29/04/2024 pm IST			5-day change	1st Jan Change
3.595 ^USD	+5.12%		-4.25%	-15.85%

03/04	Piper Sandler Trims Price Target on Sutro Biopharma to $11 From $12, Maintains Overweight Rating	MT
03/04	Truist Securities Adjusts Price Target on Sutro Biopharma to $18 From $25, Keeps Buy Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ipsen and Sutro Biopharma Announce Exclusive Global Licensing Agreement for an ADC Targeting Solid Tumors	02/04
Winfarm : Atos, Ipsen, Voltalia...les valeurs à suivre aujourd'hui à Paris -	02/04
Ipsen : signature d'un accord exclusif avec Sutro Biopharma	02/04
Ipsen : accord de licence mondiale avec Sutro Biopharma	02/04
Ipsen Signs Licensing Deal for Cancer-targeting Antibody Conjugate with Sutro Biopharma	02/04
Ipsen rachète les droits mondiaux de l'anticancéreux STRO-003 à Sutro Biopharma	02/04
Sutro Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRa-Targeting ADC	05/01
Sutro Biopharma, Inc. Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023	12/12
Vaxcyte, Inc. Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control over Manufacturing and Development of Cell-Free Extract for Its Vaccine Candidates	28/11
Sutro Biopharma, Inc Appoints Jane Chung as President and Chief Operating Officer	22/11
Sutro Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Sutro Biopharma Says Endometrial Cancer Therapy Showed 'Encouraging Preliminary Anti-Tumor Activity'	23/23/23
Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Endometrial Cancers At ESMO 2023	22/23/22
Sutro Biopharma, Inc. Appoints Hans Peter Gerber as Chief Scientific Officer	19/23/19
Sutro Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11
Sutro Biopharma, Blackstone Sign Royalty Financing Agreement	26/23/26
Sutro Biopharma and Blackstone Announces Royalty Financing Collaboration	26/23/26
Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation	15/23/15
Sutro Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Sutro Biopharma, Inc.

Equities

STRO

US8693671021

Other languages

Filters